- By Gina Chiri-Osmond
Leica Biosystems and Mayo Clinic Collaborate on Future of Cytogenetics Imaging
NUSSLOCH, Germany — Leica Biosystems and Mayo Clinic’s Department of Laboratory Medicine and Pathology announced today a collaboration to develop the next generation of cytogenetics imaging software. The new tool will optimize software workflow and improve the overall user experience for cytogenetics imaging technicians.
The two organizations intend to help cytogenetics laboratories effectively process increased case loads. Their solution will reduce manual steps in the imaging process through paperless workflow. It will also pioneer secure remote case access, which will enable flexible on- and off-shoring of case reviews.
“Our goal is to develop the fastest and most accurate cytogenetic information tool to enhance patient care,” says Patricia Greipp, D.O., co-laboratory director of the Mayo Clinic Cytogenetics Laboratory. “Mayo Clinic now has the opportunity to incorporate its expertise within an imaging solution from Leica that we feel will produce the most sophisticated and efficient cytogenetics analysis tool for the modern cytogenetics laboratory.”
Physicians and allied health staff from Mayo Clinic will provide clinical expertise throughout the collaboration with Leica. The Mayo Cytogenetics Laboratory handles more than 80,000 cases each year and is growing.
“Laboratory consolidation and a decreasing population of cytogenetics technicians are driving increasing caseloads and productivity challenges for cytogenetics laboratories,” says Donal O’Shea, Leica Biosystems vice president of clinical microscopy applications. “They need software that increases throughput and improves case turnaround time. Mayo Clinic is the gold standard for clinical practice. We feel that this collaboration will enable us to optimize our future-state workflows for improved patient experience and minimized wait times.”
Earlier this year, Mayo Clinic selected Leica Biosystems to fully renew the health care organization’s cytogenetics imaging equipment. Key selection criteria included responsiveness to Mayo’s requirements, automated scanning with multi-operator environment support, and a high-quality service offering.
Mayo Clinic has a financial interest in the technology development referenced in this news release.
About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides anatomic pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica’s easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in more than 100 countries. It has manufacturing facilities in 7 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at LeicaBiosystems.com.
About Laboratory Medicine and Pathology at Mayo Clinic
The Mayo Clinic Department of Laboratory Medicine and Pathology and its reference laboratory, Mayo Medical Laboratories, provide advanced laboratory testing and pathology services to support 4,000 health care organizations around the world. Revenue from this testing is used to support medical education and research at Mayo Clinic, a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. Complemented by collaborations with diagnostic and biotechnology companies, the department maintains a robust diagnostic test-development program, launching more than 150 new tests each year.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.
MEDIA CONTACT: Andrew Tofilon, Public Affairs, 507-284-5005, [email protected]